Autonomic Technologies, Inc.: Series A $5.0M

Autonomic Technologies (Menlo Park, CA) makers of neuromdoulation stimulation devices closed on the first $3M traunche of a $5M Series A financing. Participants in the round include Kleiner Perkins Caufield & Byers and the Cleveland Clinic.

Aerovance, Inc.: Series C $60M

Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

MAP Pharmaceuticals, Inc.: Series D $50M

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

ChemoCentryx, Inc.: Series D $29.9M

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Numira Biosciences, Inc.: Series A $2.5M

Numira Biosciences (Irvine, CA) a medical device company specializing in high resolution bone imaging and virtual histology has raised a $2.5M Series A round. The deal was led by vSpring Capital and joined by Tech Coast Angels and Pasadena Angels.

CoreValve, Inc.: Series C Series C $33M

CoreValve (Irvine, CA) is a medical device company introducing a percutaneous revalving system to replace failing aortic heart valves without surgical access closed a $33M Series C financing. The deal was led by Maverick Capital other participants included Apax Partners, HealthCap and Sofinnova Partners.

Orqis Medical Corp.: Series D $37.4M

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.

Coapt Systems, Inc.: Series E $22.6M

Coapt Systems (Palo Alto, CA) develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures raised $22.6M in a Series E financing. The deal was led by Global Life Science Ventures and Easton Capital other participants included Alta Partners, Asset Management Company, Canaan Partners, Millennia Partners and Foundation Medical Partners.

Amira Pharmaceuticals, Inc.: Series B $25M

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Tragara Pharma, Inc.: Series A $40M

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.